menu
    • menu
    [{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Terry Fox Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Perflutren","moa":"blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Oncology","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Terry Fox Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Terry Fox Research Institute"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Perflutren","moa":"blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Oncology","graph2":"Phase I","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Terry Fox Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Perflutren","moa":"blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Oncology","graph2":"Phase I","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Terry Fox Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Sunnybrook Health Sciences Centre \/ Terry Fox Research Institute"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"Lantheus Medical Imaging | Rothman Institute","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Perflutren","moa":"blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Thomas Jefferson University \/ Lantheus Medical Imaging | Rothman Institute","highestDevelopmentStatusID":"9","companyTruncated":"Thomas Jefferson University \/ Lantheus Medical Imaging | Rothman Institute"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Perflutren","moa":"blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Perflutren","moa":"||blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"Amsterdam UMC, VUmc | Futian People's Hospital | Eigen | GE Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Perflutren","moa":"blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Oncology","graph2":"Phase III","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thomas Jefferson University \/ Amsterdam UMC, VUmc | Futian People's Hospital | Eigen | GE Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Thomas Jefferson University \/ Amsterdam UMC, VUmc | Futian People's Hospital | Eigen | GE Healthcare"}]

    Find Clinical Drug Pipeline Developments & Deals for Perflutren

    Menu

    Perflutren

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Terry Fox Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients Wit...

                            Details : Definity is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 29, 2023

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Terry Fox Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Thomas Jefferson University

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Thomas Jefferson University

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Amsterdam UMC, VUmc | Futian People's Hospital | Eigen | GE Healthcare

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer

                            Details : Perflutren is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 06, 2023

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Amsterdam UMC, VUmc | Futian People's Hospital | Eigen | GE Healthcare

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Grifols International

                            Spain arrow
                            The MedTech Conference
                            Not Confirmed

                            Grifols International

                            Spain arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Pa...

                            Details : Albutein® (albumin-human injection) is an abundant protein in plasma which has antioxidant and anti-inflammatory properties, and is being investigated for the treatment of decompensated Cirrhosis.

                            Product Name : Albutein

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 18, 2023

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Terry Fox Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Ca...

                            Details : Definity is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 17, 2022

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Terry Fox Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Thomas Jefferson University

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Thomas Jefferson University

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II/ Phase III

                            Sponsor : Lantheus Medical Imaging | Rothman Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Diagnosing Compartment Syndrome With SHAPE vs Elastography

                            Details : Definity is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Chronic Exertional Compartment Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 21, 2022

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Lantheus Medical Imaging | Rothman Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Grifols International

                            Spain arrow
                            The MedTech Conference
                            Not Confirmed

                            Grifols International

                            Spain arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perflutren,Immunoglobulin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Results of Grifols' AMBAR Clinical Trial Published in Alzheimer's & Dementia

                            Details : Previously presented at various medical congresses, AMBAR findings demonstrate a slowdown in the progression of symptoms in patients with mild-to-moderate Alzheimer's.

                            Product Name : Albutein

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 27, 2020

                            Lead Product(s) : Perflutren,Immunoglobulin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Head and Neck Cancer

                            Details : Definity is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Head and Neck Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 16, 2020

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            UNC Lineberger Comprehensive Cancer Center

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            UNC Lineberger Comprehensive Cancer Center

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Lantheus Medical Imaging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

                            Details : Perflutren is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of von Hippel-Lindau Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 09, 2019

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Lantheus Medical Imaging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lantheus Medical Imaging

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Lantheus Medical Imaging

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

                            Details : Definity (Perflutren Lipid Microsphere) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Diseases.

                            Product Name : Definity

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 25, 2018

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lantheus Medical Imaging

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Lantheus Medical Imaging

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

                            Details : Definity is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 27, 2018

                            Lead Product(s) : Perflutren

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth